For growth hormone axis research, the CJC-1295/Ipamorelin blend addresses GH pulsatility through two distinct receptor pathways - GHRH receptor stimulation and ghrelin receptor agonism - providing complementary secretagogue coverage within a single preparation
As of mid-2026, roughly 11% of American adults are using a GLP-1 medication for weight loss, up from 3% in 2024, and 91% are aware these drugs exist (Gallup National Health and Well-Being Index, July 2026)
( 3 ) This led to the development and approval of GLP-1 drugs specifically for weight loss in people without diabetes
Notably, among trial participants from the Asian region, the risk of major adverse cardiovascular events (MACE) reduction was even more pronounced at 27%
Research shows that users lose 245% more weight using Noom Med with a GLP-1 (when appropriate) compared to Noom Weight
We review your history and check your B12 level so treatment is based on your actual numbers, not a guess